A
Averna Therapeutics
Redosable mRNA genomic medicines platform
About Averna Therapeutics
Averna Therapeutics, formerly known as Exsilio Therapeutics, is a biotechnology company developing genomic medicines that insert therapeutic genetic instructions into safe-harbor sites in the genome. The platform is designed for redosable treatments across genetic diseases, cancer, and autoimmune conditions using RNA delivered in lipid nanoparticles.
Averna engineers naturally occurring genetic elements encoded in messenger RNA so new genes can be inserted precisely into disease-relevant cells. Because the medicines are encoded in mRNA, they can use validated non-viral delivery approaches that support redosing with curative intent. The company targets patients and development partners in genomic medicine who need durable gene insertion without relying solely on one-time viral vectors.
Averna operates as a clinical-stage genomic medicine developer advancing its RNA/LNP insertion platform from research into therapeutic programs. Public materials describe predictive in silico modeling combined with wet-lab engineering of insertion elements, with headquarters in the Greater Boston area.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Watertown, United States
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 54.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SPINOUTOther financing | Jun 2024 | $0 | — | Weizmann Institute of Science | — |
| SERIES AOther financing | Jun 2024 | $82M | $328M | Innovation Endeavors · Invus · CRISPR Therapeutics · OrbiMed | ↗ |
Growth signals
Latest recorded traffic for Averna Therapeutics is 40 monthly website visits, down 96% over the last three months. Averna Therapeutics's team grew 1.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Averna Therapeutics in the Watertown ecosystem
The Averna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Delos Capital
Novartis Venture Fund
Innovation Endeavors
Invus
CRISPR Therapeutics
OrbiMed
ARC Ventures
Deep Insight
Insight Partners
JP Morgan
Other known investors1 additional known investor
Weizmann Institute of Science
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Averna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Averna Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









